Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan

Li, Cesheng; Ding, Yu; Wu, Xihan; Hong, Lei; Zhou, Zhijun; Xie, Yong; Li, Taojing; Wu, Jieying; Lu, Fengping; Li, Feng; Mao, Min; Lin, Lianzhen; Guo, Huanhuan; Yue, Shenglan; Wang, Feifei; Yan, Peng; Hu, Yong; Wang, Zejun; Yu, Jianhong; Zhang, Yong; Lu, Jia; Ning, Haoran; Yang, Horng Ren; Fu, Daoxing; He, Yanlin; Zhou, Dongbo; Du, Tao; Duan, Kai; Dong, Demei; Deng, Kun; Zou, Xia; Ya, Zhang; Zhou, Rong; Gao, Yang; Zhang, Xinxin; Yang, Xiaoming

doi:10.1038/s41467-021-24230-5

Cited by 60 publications

(59 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When we compared anti-S IgG levels at M10 with those at M2, we found them to be reduced in 16 subjects and upregulated in 12 (Figure 4E-G). Interestingly, we found that those who had increased anti-S IgG levels at M10 were older when compared to those who displayed decreased anti-S IgG levels at M10 (p = 0.01), as already reported in a series of studies conducted in healthy subjects [17][18][19]. Next, using the mathematical modeling approach developed by Miles P. Davenport and co-workers, which provides a quantitative prediction of the link between neutralizing antibody levels and clinical protection, we estimated the 50% protective neutralization level against SARS-CoV-2 infection in our cohort to be 78.338 in the M2 group, calculated as 20.2% of the mean level [20].…”

Section: Comparative Analysis Of the Igg Titers And The Neutralizing Response At Ten Months After The First Positive Pcr Test (M10)supporting

confidence: 86%

“…Both anti-RBD and anti-S antibody levels were below the detection limit of the assays in 7% of the subjects after ~50 days from the first SARS-CoV-2 positive PCR test, indicating that these patients did not seroconvert or had already lost their seroconversion at this time point [5,19,21]. At this time point, both anti-RBD and anti-S IgG levels were significantly higher in hospitalized subjects than those observed in asymptomatic or symptomatic patients.…”

Section: Discussionmentioning

confidence: 81%

“…Recent longitudinal studies aimed at investigating the duration of humoral immune response in COVID-19-recovered individuals reported similar decay kinetics. Overall, the decline appears to occur up to 7-9 months while it is thereafter stabilized at least until 12 months [19,[22][23][24].…”

Section: Discussionmentioning

confidence: 94%

See 2 more Smart Citations

Persistence of Neutralizing Antibodies to SARS-CoV-2 in First Wave Infected Individuals at Ten Months Post-Infection: The UnIRSA Cohort Study

Griffante

Chandel

Ferrante

et al. 2021

Viruses

View full text Add to dashboard Cite

Longitudinal mapping of antibody-based SARS-CoV-2 immunity is critical for public health control of the pandemic and vaccine development. We performed a longitudinal analysis of the antibody-based immune response in a cohort of 100 COVID-19 individuals who were infected during the first wave of infection in northern Italy. The SARS-CoV-2 humoral response was tested using the COVID-SeroIndex, Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO Kit (R&D Systems, Bio-Techne, Minneapolis, USA) and pseudotype-based neutralizing antibody assay. Using sequential serum samples collected from 100 COVID-19 recovered individuals from northern Italy—mostly with mild disease—at 2 and 10 months after their first positive PCR test, we show that 93% of them seroconverted at 2 months, with a geometric mean (GeoMean) half-maximal neutralization titer (NT50) of 387.9. Among the 35 unvaccinated subjects retested at 10 months, 7 resulted seronegative, with an 80% drop in seropositivity, while 28 showed decreased anti-receptor binding domain (RBD) and anti-spike (S) IgG titers, with a GeoMean NT50 neutralization titer dropping to 163.5. As an NT50 > 100 is known to confer protection from SARS-CoV-2 re-infection, our data show that the neutralizing activity elicited by the natural infection has lasted for at least 10 months in a large fraction of subjects.

show abstract

Section: Comparative Analysis Of the Igg Titers And The Neutralizing Response At Ten Months After The First Positive Pcr Test (M10)supporting

confidence: 86%

Section: Discussionmentioning

confidence: 81%

See 1 more Smart Citation

Persistence of Neutralizing Antibodies to SARS-CoV-2 in First Wave Infected Individuals at Ten Months Post-Infection: The UnIRSA Cohort Study

Griffante

Chandel

Ferrante

et al. 2021

Viruses

View full text Add to dashboard Cite

show abstract

“…A recent 12-month longitudinal study was published with 1,782 plasma samples from 869 convalescent plasma donors in Wuhan, China. This study has shown that among COVID-19 plasma donors the positive rate of IgG antibody against the SARS-CoV-2 receptor binding domain (RBD) in the spike protein exceeded 70% for 12 months post-diagnosis(C. Li et al, 2021).…”

Section: Discussionmentioning

confidence: 99%

Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection

Israel

Shenhar

Green

et al. 2021

Preprint

112

View full text Add to dashboard Cite

BackgroundImmune protection following either vaccination or infection with SARS-CoV-2 decreases over time.ObjectiveTo determine the kinetics of SARS-CoV-2 IgG antibodies following administration of two doses of BNT162b2 vaccine, or SARS-CoV-2 infection in unvaccinated individuals.MethodsAntibody titers were measured between January 31, 2021, and July 31, 2021 in two mutually exclusive groups: i) vaccinated individuals who received two doses of BNT162b2 vaccine and had no history of previous infection with COVID-19 and ii) SARS-CoV-2 convalescents who had not received the vaccine.ResultsA total of 2,653 individuals fully vaccinated by two doses of vaccine during the study period and 4,361 convalescent patients were included. Higher SARS-CoV-2 IgG antibody titers were observed in vaccinated individuals (median 1581 AU/mL IQR [533.8-5644.6]) after the second vaccination, than in convalescent individuals (median 355.3 AU/mL IQR [141.2-998.7]; p<0.001). In vaccinated subjects, antibody titers decreased by up to 40% each subsequent month while in convalescents they decreased by less than 5% per month. Six months after BNT162b2 vaccination 16.1% subjects had antibody levels below the seropositivity threshold of <50 AU/mL, while only 10.8% of convalescent patients were below <50 AU/mL threshold after 9 months from SARS-CoV-2 infection.ConclusionsThis study demonstrates individuals who received the Pfizer-BioNTech mRNA vaccine have different kinetics of antibody levels compared to patients who had been infected with the SARS-CoV-2 virus, with higher initial levels but a much faster exponential decrease in the first group.FundingThis research was internally funded by Leumit Health Services (LHS) and was supported in part by the Intramural Research Program, National Institutes of Health, National Cancer Institute, Center for Cancer Research.The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.Impact statementLarge scale study display the kinetics of SARS-CoV-2 IgG antibodies present in individuals vaccinated with two doses of mRNA vaccine vs. unvaccinated patients who had recovered from the disease: initial levels of antibody are much higher in vaccinated patients, but decrease faster.

show abstract

“…Following recovery of COVID-19 patients, specific IgG antibodies can last for at least 12 months in 70-90% of the convalescent COVID-19 patients who showed severe symptoms and were hospitalized [101][102][103][104][105]. The IgG titers remain in higher titers within the first 6 months of convalescence and maintain stability for the following second 6 months [101][102][103]. In mild-to-moderate patients, the IgG titers persist relatively high titers for more than 6 months after recovery [104].…”

Section: Immune Response To Coronavirus Infectionmentioning

confidence: 99%

Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview

et al. 2021

View full text Add to dashboard Cite

Respiratory viruses represent a major public health concern, as they are highly mutated, resulting in new strains emerging with high pathogenicity. Currently, the world is suffering from the newly evolving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus is the cause of coronavirus disease 2019 (COVID-19), a mild-to-severe respiratory tract infection with frequent ability to give rise to fatal pneumonia in humans. The overwhelming outbreak of SARS-CoV-2 continues to unfold all over the world, urging scientists to put an end to this global pandemic through biological and pharmaceutical interventions. Currently, there is no specific treatment option that is capable of COVID-19 pandemic eradication, so several repurposed drugs and newly conditionally approved vaccines are in use and heavily applied to control the COVID-19 pandemic. The emergence of new variants of the virus that partially or totally escape from the immune response elicited by the approved vaccines requires continuous monitoring of the emerging variants to update the content of the developed vaccines or modify them totally to match the new variants. Herein, we discuss the potential therapeutic and prophylactic interventions including repurposed drugs and the newly developed/approved vaccines, highlighting the impact of virus evolution on the immune evasion of the virus from currently licensed vaccines for COVID-19.

show abstract

Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan

Cited by 60 publications

References 32 publications

Persistence of Neutralizing Antibodies to SARS-CoV-2 in First Wave Infected Individuals at Ten Months Post-Infection: The UnIRSA Cohort Study

Persistence of Neutralizing Antibodies to SARS-CoV-2 in First Wave Infected Individuals at Ten Months Post-Infection: The UnIRSA Cohort Study

Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection

Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview

Contact Info

Product

Resources

About